Myelodysplastic syndromes (MDS) are hematopoietic malignancies characterized by
peripheral cytopenias in the face of normo-or hypercellular, dysplastic bone marrow that
arise from mutations in the hematopoietic stem/progenitor cell (HSPC). The disease is
characterized by multiple cytogenetic and molecular defects, which result in an extremely
heterogeneous phenotype. Recently, significant efforts have been made to develop
appropriate mouse models to study this complex disease. Because of the heterogeneity of …